ASH 2022 | Lintuzumab-Ac225 combined with venetoclax for R/R AML: early results
Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, discusses a novel treatment approach for relapsed/refractory (R/R) acute myeloid leukemia (AML) using radioimmunotherapy combined with venetoclax, and outlines findings from a recent investigation. Dr Schiller first explains the mechanism of action of the radiolabeled antibody lintuzumab-Ac225, and then goes on to discuss early findings from an ongoing Phase I dose escalation trial investigating this agent in combination with venetoclax. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Constellation: Research Funding; Sellas: Research Funding; Samus: Research Funding; Sangamo: Research Funding; Amgen: Current equity holder in publicly-traded company, Honoraria; Medimmune: Research Funding; FujiFilm: Research Funding; Millennium: Research Funding; Daiichi-Sankyo: Research Funding; Stemline: Research Funding; Deciphera: Research Funding; Genentech-Roche: Research Funding; Gilead: Research Funding; Karyopharm: Research Funding, Speakers Bureau; Incyte: Other: speaker fees, Research Funding, Speakers Bureau; Deltafly: Research Funding; CTI: Research Funding; Ono Pharma: Honoraria; Arog: Research Funding; Forma: Research Funding; Novartis: Honoraria, Other: Speaker fees, Research Funding; Johnson & Johnson: Current equity holder in publicly-traded company; AVM Biopharma: Research Funding; Cellectis: Research Funding; Trovagen: Research Funding; Glycomimetics: Research Funding; Pfizer: Research Funding; AstraZeneca: Honoraria; Kite, a Gilead Company: Research Funding, Speakers Bureau; Cyclacel: Research Funding; AltruBio: Research Funding; Celgene: Consultancy, Research Funding, Speakers Bureau; Janssen: Research Funding; Stemline: Speakers Bureau; Mateon: Research Funding; Geron: Research Funding; Cellerant: Research Funding; Regimmune: Research Funding; PreCOG LLC: Research Funding; Actuate: Research Funding; Jazz: Consultancy; Onconova: Research Funding; Gamida: Research Funding; Takeda: Research Funding; Tolero: Research Funding; Bristol Myers Squibb: Current equity holder in publicly-traded company, Speakers Bureau; Astellas: Research Funding, Speakers Bureau; Agios: Consultancy, Honoraria; Actinium: Research Funding; AbbVie: Research Funding, Speakers Bureau.
